Statement: There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial, than in cohort 1.
Primary_evidence: Adverse Events 1:   Total: 127/368 (34.51%)   ANAEMIA 3/368 (0.82%)   LEUKOPENIA 0/368 (0.00%)   NEUTROPENIA 0/368 (0.00%)   COAGULOPATHY 3/368 (0.82%)   LYMPHADENOPATHY 0/368 (0.00%)   THROMBOCYTOPENIA 2/368 (0.54%)   BONE MARROW FAILURE 0/368 (0.00%)   FEBRILE NEUTROPENIA 4/368 (1.09%)   DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%)   ATRIAL FLUTTER 0/368 (0.00%)   CARDIAC ARREST 0/368 (0.00%) Adverse Events 2:   Total: 151/369 (40.92%)   ANAEMIA 11/369 (2.98%)   LEUKOPENIA 6/369 (1.63%)   NEUTROPENIA 18/369 (4.88%)   COAGULOPATHY 0/369 (0.00%)   LYMPHADENOPATHY 1/369 (0.27%)   THROMBOCYTOPENIA 7/369 (1.90%)   BONE MARROW FAILURE 1/369 (0.27%)   FEBRILE NEUTROPENIA 15/369 (4.07%)   DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)   ATRIAL FLUTTER 1/369 (0.27%)   CARDIAC ARREST 1/369 (0.27%)